Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 10

1.

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

Grisham RN, Sylvester BE, Won H, McDermott G, DeLair D, Ramirez R, Yao Z, Shen R, Dao F, Bogomolniy F, Makker V, Sala E, Soumerai TE, Hyman DM, Socci ND, Viale A, Gershenson DM, Farley J, Levine DA, Rosen N, Berger MF, Spriggs DR, Aghajanian CA, Solit DB, Iyer G.

J Clin Oncol. 2015 Dec 1;33(34):4099-105. doi: 10.1200/JCO.2015.62.4726. Epub 2015 Aug 31.

PMID:
26324360
2.

Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.

Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, DeLair D, Hyman DM, Aghajanian C.

Int J Gynecol Cancer. 2014 Jul;24(6):1010-4. doi: 10.1097/IGC.0000000000000190.

3.

Abdominopelvic washings: A comprehensive review.

Rodriguez EF, Monaco SE, Khalbuss W, Austin RM, Pantanowitz L.

Cytojournal. 2013 Apr 24;10:7. doi: 10.4103/1742-6413.111080. Print 2013.

4.

BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.

Grisham RN, Iyer G, Garg K, DeLair D, Hyman DM, Zhou Q, Iasonos A, Berger MF, Dao F, Spriggs DR, Levine DA, Aghajanian C, Solit DB.

Cancer. 2013 Feb 1;119(3):548-54. doi: 10.1002/cncr.27782. Epub 2012 Aug 28.

5.

A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.

Hannibal CG, Vang R, Junge J, Kjaerbye-Thygesen A, Kurman RJ, Kjaer SK.

Gynecol Oncol. 2012 Jun;125(3):655-60. doi: 10.1016/j.ygyno.2012.02.028. Epub 2012 Feb 24.

6.

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM.

Am J Pathol. 2010 Oct;177(4):1611-7. doi: 10.2353/ajpath.2010.100212. Epub 2010 Aug 27.

7.

p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.

Anderson KS, Wong J, Vitonis A, Crum CP, Sluss PM, Labaer J, Cramer D.

Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):859-68. doi: 10.1158/1055-9965.EPI-09-0880. Epub 2010 Mar 3.

8.

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Vang R, Shih IeM, Kurman RJ.

Adv Anat Pathol. 2009 Sep;16(5):267-82. doi: 10.1097/PAP.0b013e3181b4fffa. Review.

9.

Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis.

Ayhan A, Kurman RJ, Yemelyanova A, Vang R, Logani S, Seidman JD, Shih IeM.

Am J Surg Pathol. 2009 Aug;33(8):1220-4. doi: 10.1097/PAS.0b013e3181a24354.

10.

Ovarian cancer.

Cho KR, Shih IeM.

Annu Rev Pathol. 2009;4:287-313. doi: 10.1146/annurev.pathol.4.110807.092246. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk